# A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

> **NCT04272957** · PHASE1 · UNKNOWN · sponsor: **Hutchison Medipharma Limited** · enrollment: 75 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** HMPL-306

## Key facts

- **NCT ID:** NCT04272957
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-14
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272957, "A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04272957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*